Gfs Advisors Upped Coca Cola Femsa S A B De C V (KOF) Position By $359,100; Broadfin Capital Cut Its Redhill Biopharma LTD (RDHL) Stake

July 18, 2017 - By Marguerite Chambers

Broadfin Capital Llc decreased Redhill Biopharma Ltd (RDHL) stake by 64.93% reported in 2016Q4 SEC filing. Broadfin Capital Llc sold 465,694 shares as Redhill Biopharma Ltd (RDHL)’s stock rose 0.20%. The Broadfin Capital Llc holds 251,509 shares with $2.63 million value, down from 717,203 last quarter. Redhill Biopharma Ltd now has $153.27 million valuation. The stock declined 0.56% or $0.05 reaching $8.88 per share. About 1,423 shares traded. RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) has declined 9.09% since July 18, 2016 and is downtrending. It has underperformed by 25.79% the S&P500.

Gfs Advisors Llc increased Coca Cola Femsa S A B De C V (KOF) stake by 60.45% reported in 2016Q4 SEC filing. Gfs Advisors Llc acquired 5,700 shares as Coca Cola Femsa S A B De C V (KOF)’s stock rose 21.16%. The Gfs Advisors Llc holds 15,130 shares with $961,000 value, up from 9,430 last quarter. Coca Cola Femsa S A B De C V now has $6.25 billion valuation. It closed at $90.1 lastly. It is down 2.10% since July 18, 2016 and is downtrending. It has underperformed by 18.80% the S&P500.

Gfs Advisors Llc decreased Ishares Tr (IWD) stake by 6,259 shares to 27,235 valued at $3.05 million in 2016Q4. It also reduced Vanguard Index Fds (VBR) stake by 5,606 shares and now owns 12,273 shares. General Electric Co (NYSE:GE) was reduced too.

Among 7 analysts covering Coca-Cola FEMSA (NYSE:KOF), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Coca-Cola FEMSA had 17 analyst reports since July 24, 2015 according to SRatingsIntel. Goldman Sachs downgraded the stock to “Neutral” rating in Friday, January 15 report. The rating was upgraded by Credit Suisse on Thursday, September 8 to “Outperform”. Barclays Capital maintained the stock with “Overweight” rating in Friday, October 14 report. Santander downgraded Coca-Cola FEMSA, S.A.B. de C.V. (ADR) (NYSE:KOF) on Friday, September 11 to “Hold” rating. As per Wednesday, September 14, the company rating was upgraded by Citigroup. The rating was maintained by JP Morgan with “Neutral” on Friday, June 3. On Friday, May 12 the stock rating was upgraded by JP Morgan to “Overweight”. Goldman Sachs downgraded the stock to “Neutral” rating in Monday, January 18 report. The rating was maintained by Barclays Capital on Monday, March 7 with “Overweight”. The rating was downgraded by Nomura on Monday, January 11 to “Reduce”.

Analysts await RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) to report earnings on July, 25. They expect $-0.58 EPS, up 3.33% or $0.02 from last year’s $-0.6 per share. After $-0.50 actual EPS reported by RedHill Biopharma Ltd – ADR for the previous quarter, Wall Street now forecasts 16.00% negative EPS growth.

Broadfin Capital Llc increased Idera Pharmaceuticals Inc (NASDAQ:IDRA) stake by 2.00 million shares to 4.43M valued at $6.64M in 2016Q4. It also upped Durect Corp (NASDAQ:DRRX) stake by 2.11M shares and now owns 8.51M shares. Teva Pharmaceutical Inds Ltd (NYSE:TEVA) was raised too.